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The time to reperfusion with E601 0 was shorter than that with native t-PA.
Coronary recanalization at 30 and 60 minutes after administration was ob-
tained in 61.9% and 79.4% of the case with E6010 and in 32.4% and 64.7%
of the case with native t-PA, and the difference between both were statisti-
cally significant. No fatal bleeding complications were observed in E601 O. 4
patients (3.8%1 in E6010 and 3 patients (2.8%) in native t-PA died during 48
days post treatment hospitalization.
Discussion and Conclusion: Native t-PA is required to be administered over
period of 1 hr with 10% of the total dose administered as an i.v. bolus and the
remainder infused i.v. over 1 hr. Our present results indicate that E601 0 can
be easily administered by i.v. bolus injection taking 2-3 minutes and it exerts
a valuable thrombolytic effects, namely a high rate and early recanalization
of infarct-related arteries.
Randomized, Double-Blind Multicenter Trial of a
Novel Modified t-PA, E6010 by Lv. Bolus Injection in
Treatment of Acute Myocardial Infarction (AMI) -
Comparison with Native t-PA
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E6010 is a novel modified t-PA, in which cysteine 84 in the epidermal growth
factor domain has been replaced by serine. This is the first modified t-PA to
be effective by i.v. bolus injection, and it has a prolonged half-life (Ta1/2 >
20 min) compared to native t-PA.
A randomized, double-blind multicenter trial of Lv. bolus injection of E601 0,
27,500 EU/kg, compared with native t-PA (cell culture). 14.400,000 IU has
been performed in the treatment of AMI of ~6 hr duration and total occlu-
sion of the infarct-related arteries. Angiograms were used to evaluate the
patency of infarct-related arteries at 15, 30, 45, and 60 minutes after the ad-
ministration. Result:
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Few data exist regarding the need for noninvasive testing after reperfusion
therapy in myocardial patients at low clinical risk. Moreover, after thromboly-
sis, recurrent ischemia occurs frequently and unpredictably and has resulted
in physician reluctance to shorten the length of hospitalization in these pa-
tients. Alternatively, emergency catheterization with primary PTCA may pro-
vide acute determination of risk status, a stable method of reperfusion and
the potential for early discharge. The objective of this multicenter study was
to prospectively test the hypothesis that early discharge (day 31 without non-
invasive risk stratification in low risk MI patients treated with primary angio-
plasty is safe, feasible, and cost effective. Patients with acute myocardial
infarction 0-12 hrs who had an emergency catheterization and immediate
PTCA of the infarct related artery were stratified into a low risk group if age
~70 yrs, 1 or 2 vessel disease, EF > 45%, successful infarct vessel PTCA and
no malignant arrhythmias persisted after the PTCA. Low risk patients were
randomized to admission to either the intenSive care unit (with hospitaliza-
tion a minimum of 5 days and predischarge exercise testing) or admission
to a non-intensive care PTCA unit with no non-'Invasive testing and discharge
on day 3. To date, 340 of the anticipated 400 patients have been enrolled.
The mean age was 56 ± 9, estimated ejection fraction 56 ± 9 and 74% had
single vessel disease. As expected, in-hospital complications occurred infre-
quently; death 1.1 %, recurrent MI 1.7%; stroke 0.6%; heart failure 4.6%.
At 1 week follow-up, no complications attributed to early discharge have
occurred. Thus, acute catheterization does allow identification of low risk MI
patients who can be safely admitted to an elective PTCA unit and discharged
in 3 days without additional testing. Complete data on the 400 patient cohort
including cost and 6 week follow-up will be available by March 1995
To evaluate the role of immediate intravenous (IV) fJ blockade in patients
treated with thrombolytic agents and aspirin for acute myocardial infarction,
we compared the outcome in the group of patients enrolled in the GUSTO
trial who received atenolol IV followed by oral dose (gr.A, n = 16406) with
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Psychophysiological Investigations of Myocardial
Ischemia (PIMI): Initial Results on Mechanisms of
Cardiac Ischemia
The Survival Advantage of Early Grade 3 Patency
After Thrombolysis for Infarction Increases Over
Time
ACUTE MYOCARDIAL INFARCTION/UNSTABLE ANGINA-
LONG-TERM OUTCOME
The survival advantage for thrombolytic treated infarct patients who exhibit
prompt (90') full coronary patency, grade 3, (versus incomplete, 2, or absent
flow, 0,1) is well established at time points of one week or one month. The
GUSTO angiographic study now allows inspection of subsequent changes,
if any, in the flow grade specific patency-mortality relationships to one full
year's follow up. Of 1173 patients in whom infarct artery (IRA) patency grade
was established angiographically 90' after treatment was begun, 12 month
follow up is available in 99.9% (1172). Patency-1 year mortality relationships
were:
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shock assisted with the intraaortic balloon pump.
In conclusion, IV Am administration is highly effective in restoring sinus
rhythm in AF complicating AMI and is well tolerated.
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Psychological factors are linked to outcomes in coronary artery disease
(CAD) pts but the mechanisms are obscure. The PIMI is a NIH multicenter
study designed to test the overall hypothesis that manifestations and ex-
pressions of ischemia are influenced by specific psycho-physiologic mecha-
nisms. Accordingly, 200 pts, mean age 62, with CAD and ischemia responses
on treadmill were studied. Ambulatory ECG (AECG) monitoring, psychologi-
cal instrument batteries and plasma biochemical tests were applied to iden-
tify mechanisms associated with ischemia during daily life, exercise and
mental stress without influence of cardiac medications. Daily life ischemia
(AECGI occurred in 41% of pts (95% with ischemia were asymptomatic)
and was associated with lower hostility (p < 0.01) and anger expression
(p < 0.03) scores compared with those without daily life ischemia. An in-
verse association between magnitude of daily life ischemia and these scores
was observed. No differences were found for depression (Beck) or anxiety
scores. On treadmill all pts had ischemia (ST segment depression) but 44%
had angina. Angina expression was associated with higher depression (p =
0.002), anxiety (State, p = 0.002 and Trait. p = 0.01) and autonomic percep-
tion (p ~ 0.05) scores than no angina. Depression best predicted time to
angina (Cox model. p ~ 0.007).
During mental stress (Stroop and speech tasks) ischemia (radionuclide
ventriculogram (RVG) or ST segment abnormalities) occurred in 79% of pts
(95% with ischemia were asymptomatic) and associated with higher Re-
ward, Dependence, (Temperament and Character Inventory, p < 0.02) and
level of irritation during Stroop task (p < 0.01). Plasma norepinephrine re-
mained low, but epinephrine doubled and systolic pressure increased. No
associations were found for medical or demographic factors examined. Dur-
ing bicycle exercise ischemia (RVG abnormality) occurred in 94% of pts (64%
with ischemia were asymptomatic) yet norepinephrine increased three-fold.
In summary, daily life ischemia (usually asymptomatic) is associated with
suppressed hostility, anger and emotion but not depression or anxiety. Men-
tal stress ischemia (mostly asymptomatic and with epinephrine release) is re-
lated to temperament characteristics. Exercise stress ischemia, on the other
hand, more often evokes symptoms and marked norepinephrine release but
symptom expression seems dependent upon depression, anxiety and auto-
nomic perception. Mechanisms responsible for ischemia evoked in different
settings and its symptomatic expression involve complex interactions of be-
havioral, physiological and psychophysiological factors.
Genetic Predisposition to Neurohumoral
Activation Following Myocardial Infarction: Effects
of the Angiotensin Converting Enzyme I/O
Polymorphism
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death-n (%) CHF(%) ischemia (%) v. fib(%) pacing (%) shock (%)
gr. A 504(31) 14.3 22.1 5.4 60 33
gr. B 214(30) 10.7 18.9 4.7 4.0 22
P NS P< 0.01 P < 001 NS P < 001 P < 001
Intravenous Amiodarone Restores Sinus Rhythm
in Acute Myocardial Infarction Complicated with
Atrial Fibrillation
Recent studies suggest that a deletion polymorphism of the angiotensin
converting enzyme (ACE) gene is associated with increased plasma ACE
activity and an increased risk for both, myocardial infarction (MI) and left
ventricular hypertrophy (LVH). To test the hypothesis whether the deletion
ACE genotype also affects neurohumoral activation following MI. we stud-
ied 96 patients, 59 ± 9 years of age, with acute anterior MI, no overt heart
failure, or need for ACE-inhibition. Subjects were randomized to treatment
with either captopril or placebo following thrombolytic therapy. Bloodsam-
pies for plasma norepinephrine and ACE activity were taken at baseline (be-
fore thrombolysis) and 1, 12 and 24 hours after thrombolysis. ACE genotyp-
ing (polymerase chain reaction; specific primers amplifying 190 bp and 490
bp fragments of deletion [0] and insertion [I] alleles, respectively) was car-
ried out at the end of follow-up, without knowledge of clinical parameters.
At baseline, norepinephrine levels were equal in DO, I/O and II groups. In
contrast, the increase of norepinephrine levels was more pronounced in MI
patients with DO (n = 34; 556 ± 189 pg/ml) as compared to 10 and II geno-
type (n = 62; 96 ± 98 pg/ml; p < 0.01). Furthermore, baseline ACE activity
was higher in the DO genotype group (29 ± 3 vs 23 ± 2 U/I; p = 0.01) This
increased response in DO genotype patients was blunted by captopril. As-
sociation of the DO genotype and adverse neurohumoral activation was still
evident after correction for infarct size and captopril treatment (p < 0.01)
Thus, the ACE/DO genotype appears to increase the risk for neurohumoral
activation after anterior MI and DO genotype patients benefit most from early
ACE inhibition.
The effectiveness and tolerance of intravenous (IV) amiodarone (Am) in atrial
fibrillation (AF) complicated acute myocardial infarction (AMI) is not well stud-
ied. Thus, twenty patients !pts) with AMI complicated with AF occurring
within 30 h (11.9 ± 10) of the onset of AMI symptoms were treated with
IV administration of digitalis (d, 0.5 mg and an additional 025 mg later) fol-
lowed by IV Am 300 mg over 2 h (starting 2 h after the initial dose of d) and
followed by 44 mg/h for up to 3 days, if sinus rhythm (SR) was not restored.
Intravenous d restored SR within 2 h in 5/20 pts. AF relapsed in 2 of them.
Subsequent administration of Am for 2 h restored SR in the remaining 15/20
pts and in the 2 pts in whom AF had relapsed after the initial restoration of
SR by d. Am restored SR within an average of 12.8 (range 0.5-56) h of infu-
sion. Total dose of Am was 1922 ± 720 mg in 4 pts and 425 ± 241 mg in the
remaining 13. Am was well tolerated by all pts including 1 with cardiogenic
Wiek H. van Gilst, Yigal M. Pinto, J. Herre Kingma, Heribert Schunkert, CATS
Investigators. Dept. of Clinical Pharmacology, Gromngen, NL; Klinik fur Innere Medizln
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the group receiving it only orally within the first 24 hours (gr.B. n = 6732).
GUSTO tested four regimens of thrombolysis: accelerated t-PA with IV hep-
arin, streptokinase (SK) with IV/subcutaneous heparin and combination of
t-PA and SK with IV heparin, in 41,021 patients. Atenolol was administered,
if not contraindicated, as two doses of 5 mg. IV. every 15 minutes followed by
50-100 mg. orally every day. In 9987 patients, there were contra indications
to its use, as perceived by the enrolling physician. The baseline character-
istics of the patients receiving IV atenolol were not unfavorable in terms of
previous infarction, Killip class, assignment to t-PA, age, systolic pressure,
heart rate or time to treatment, when compared with the whole cohort re-
ceiving atenolol within the first 24 hours. The main events are listed below:
(CHF - congestive heart failure, v.fib - ventricular fibrillation):
There was a similar incidence of reinfarction and angiographic reocclusion
in the 2 groups. Although not a randomized comparison, the utilization of IV
atenoloI in the first 24 hours after myocardial infarction, was paradoxically
associated with increased morbidity, when compared to the more gradual
oral fJ blockade.
1901-41
6A
